Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD,

Slides:

Advertisements

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Advertisements

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: A double-blind randomized controlled trial Saifudin.

Defective B-cell memory in patients with Down syndrome Ruud H.J. Verstegen, MD, Gertjan J. Driessen, MD, Sophinus J.W. Bartol, BSc, Carel J.M. van Noesel,

Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007 Raymond James Mullins, MBBS, PhD, FRACP, FRCPA, Keith B.G.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Allergen immunotherapy: A practice parameter third update

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Fatty acids, inflammation, and asthma

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012 Anni Nørgaard Jeppesen, MD, Christian Fynbo.

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Etiology of asthma exacerbations

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Reply Journal of Allergy and Clinical Immunology

Phillip Lieberman, MD, Michael Tankersley, MD

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Phillip Lieberman, MD, David Golden, MD

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Effect of ingested H1 antihistamines on methacholine challenge

News Beyond Our Pages Journal of Allergy and Clinical Immunology

What is an “eosinophilic phenotype” of asthma?

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Mary F. Linehan, PhD, Timothy L. Frank, MD, Michelle L

Bruce G. Bender, PhD, Alex Pedan, PhD, Laleh T. Varasteh, RPh, MSF

Exposure of infants to budesonide through breast milk of asthmatic mothers Anette Fält, BSc, Thomas Bengtsson, MSc, Britt-Marie Kennedy, BSc, Ann Gyllenberg,

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen- induced asthmatic reactions Emmerentia van Schalkwyk, MBChB, K. Strydom,

Acid-suppressive drug use in pregnancy and the toddler's asthma risk: A crossover, case-control study Bianca Mulder, BSc, Catharina Carolina Maria Schuiling-Veninga,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Macrolide antibiotics and asthma treatment

Neil W. Johnston, MSc, Sebastian L. Johnston, MD, PhD, Joanne M

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Environmental factors and eosinophilic esophagitis

The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy Jennifer M. Maloney, MD, Magnus Rudengren, BSc, Staffan.

Advances in pediatric asthma in 2007

Confirmation and improvement of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate cohorts Helen Chapel, MA,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Presentation transcript:

Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down Eric D. Bateman, MD, Loretta Jacques, PhD, Caroline Goldfrad, MSc, Tito Atienza, MD, Triaian Mihaescu, MD, Marie Duggan, BSc Journal of Allergy and Clinical Immunology Volume 117, Issue 3, Pages 563-570 (March 2006) DOI: 10.1016/j.jaci.2005.11.036 Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Study design. Patients were considered eligible for randomization if they fulfilled the criteria for well controlled asthma during each of the last 4 weeks of the open-label period. prn, As needed; b.i.d., twice daily. Journal of Allergy and Clinical Immunology 2006 117, 563-570DOI: (10.1016/j.jaci.2005.11.036) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Flow of patients in study. Journal of Allergy and Clinical Immunology 2006 117, 563-570DOI: (10.1016/j.jaci.2005.11.036) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Percentage of subjects achieving asthma control during each week of the study (ITT population). A, Well controlled asthma. B, Total control of asthma. Only patients who were randomized to double-blind treatment are presented. Includes 53 patients who were randomized even though they had not achieved well-controlled asthma over weeks 9-12 of the open-label phase. bid, Twice daily. Journal of Allergy and Clinical Immunology 2006 117, 563-570DOI: (10.1016/j.jaci.2005.11.036) Copyright © 2006 American Academy of Allergy, Asthma and Immunology Terms and Conditions